PRALUENT® (alirocumab) Mechanism of Action

Bringing innovation to life: PRALUENT helps lower LDL-C levels by inhibiting PCSK91


PRALUENT is a human monoclonal antibody that binds to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

  • PCSK9 binds to low-density lipoprotein receptors (LDLRs) on the surface of hepatocytes to promote LDLR degradation within the liver1
  • LDLR is the primary receptor that clears circulating low-density lipoprotein (LDL), therefore the decrease in LDLR levels by PCSK9 results in higher blood levels of LDL-C1

By inhibiting the binding of PCSK9 to LDLR, PRALUENT increases the number of LDLRs available to clear LDL, thereby lowering LDL-C levels

Reference:
  1. PRALUENT® (alirocumab) Prescribing Information. Sanofi/Regeneron Pharmaceuticals, 2017.

Download Resources